$RENB
RENOVARO INC. Stock $renb

$renb Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000173112223000321 Filed on March 07, 2023

Income Statement

Concept	2022 Q3	2021 Q3
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.557M	$4.467M
YoY Change	2.02%	150.94%
% of Gross Profit
Research & Development	$2.605M	$3.006M
YoY Change	-13.33%	186.31%
% of Gross Profit
Depreciation & Amortization	$28.40K	$31.73K
YoY Change	-10.49%	5.77%
% of Gross Profit
Operating Expenses	$7.191M	$7.505M
YoY Change	-4.18%	162.4%
Operating Profit	-$7.191M	-$7.505M
YoY Change	-4.18%	162.4%
Interest Expense	$95.59K	-$82.62K
YoY Change	-215.69%	-8.2%
% of Operating Profit
Other Income/Expense, Net	-$509.1K	-$2.825M
YoY Change	-81.97%
Pretax Income	-$7.700M	-$10.41M
YoY Change	-26.05%	313.17%
Income Tax		$30.00
% Of Pretax Income
Net Earnings	-$7.700M	-$10.41M
YoY Change	-26.05%	333.83%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.14
Diluted Earnings Per Share	-$0.14	-$199.4K
COMMON SHARES
Basic Shares Outstanding	55.10M shares
Diluted Shares Outstanding	55.10M shares

Balance Sheet

Concept	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.972M	$15.38M
YoY Change	-48.16%	156.28%
Cash & Equivalents	$7.972M	$15.38M
Short-Term Investments
Other Short-Term Assets	$160.6K	$78.11K
YoY Change	105.65%	-21.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$8.133M	$15.46M
YoY Change	-47.38%	153.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$559.6K	$2.064M
YoY Change	-72.89%	-14.0%
Goodwill	$11.64M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$74.38M	$20.98K
YoY Change	354420.44%	-79.02%
Total Long-Term Assets	$74.94M	$168.6M
YoY Change	-55.56%	-0.23%
TOTAL ASSETS
Total Short-Term Assets	$8.133M	$15.46M
Total Long-Term Assets	$74.94M	$168.6M
Total Assets	$83.07M	$184.1M
YoY Change	-54.87%	5.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.683M	$547.9K
YoY Change	754.72%	82.62%
Accrued Expenses	$1.042M	$662.7K
YoY Change	57.28%	32.53%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.200M
YoY Change
Total Short-Term Liabilities	$7.159M	$1.211M
YoY Change	491.4%	51.32%
LONG-TERM LIABILITIES
Long-Term Debt	$4.652M	$5.853M
YoY Change	-20.53%	-0.79%
Other Long-Term Liabilities	$934.9K	$10.03M
YoY Change	-90.68%	138.71%
Total Long-Term Liabilities	$5.587M	$15.88M
YoY Change	-64.82%	57.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.159M	$1.211M
Total Long-Term Liabilities	$5.587M	$15.88M
Total Liabilities	$12.75M	$17.09M
YoY Change	-25.42%	56.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$212.0M
YoY Change
Common Stock	$5.552K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$70.32M	$167.0M
YoY Change
Total Liabilities & Shareholders Equity	$83.07M	$184.1M
YoY Change	-54.87%	5.12%

Cashflow Statement

Concept	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$7.700M	-$10.41M
YoY Change	-26.05%	333.83%
Depreciation, Depletion And Amortization	$28.40K	$31.73K
YoY Change	-10.49%	5.77%
Cash From Operating Activities	-$2.820M	-$5.277M
YoY Change	-46.55%	91.18%
INVESTING ACTIVITIES
Capital Expenditures		-$5.160K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities		-$5.160K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.625M
YoY Change
NET CHANGE
Cash From Operating Activities	-$2.820M	-5.277M
Cash From Investing Activities		-5.160K
Cash From Financing Activities	$1.625M
Net Change In Cash	-$1.200M	-5.282M
YoY Change	-77.28%	91.37%
FREE CASH FLOW
Cash From Operating Activities	-$2.820M	-$5.277M
Capital Expenditures		-$5.160K
Free Cash Flow	-$2.820M	-$5.272M
YoY Change	-46.5%	91.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001527728
CY2022Q3	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q3	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	enob	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration		usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1		usd
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2021Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021Q3	enob	Common Shares Issued For Contingent Earn Out Liability CommonSharesIssuedForContingentEarnOutLiability		usd
CY2022Q3	enob	Period Changes PeriodChanges		usd
CY2021Q3	us-gaap	Sublease Income SubleaseIncome		usd
CY2022Q3	dei	Document Type DocumentType	10-Q
CY2022Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q3	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
CY2022Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q3	dei	Entity File Number EntityFileNumber	001-38758
CY2022Q3	dei	Entity Registrant Name EntityRegistrantName	Enochian Biosciences Inc.
CY2022Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2559340
CY2022Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	1927 Paseo Rancho Castillo
CY2022Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
CY2022Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90032
CY2022Q3	dei	City Area Code CityAreaCode	(305)
CY2022Q3	dei	Local Phone Number LocalPhoneNumber	918-1980
CY2022Q3	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022Q3	dei	Trading Symbol TradingSymbol	ENOB
CY2022Q3	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9172142	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	160629	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	392996	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	8132547	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	9565138	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	559621	usd
CY2022Q3	us-gaap	Goodwill Goodwill	11640000	usd
CY2022Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q3	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55705521	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7971918	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	586536	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39953	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	44268	usd
CY2022Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	61571000	usd
CY2022Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	61571000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	11640000	usd
CY2022Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	65285	usd
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	68635	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1062150	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1157086	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	74378388	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	74480989	usd
CY2022Q3	us-gaap	Assets Assets	83070556	usd
CY2022Q2	us-gaap	Assets Assets	84632663	usd
CY2022Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4682745	usd
CY2022Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1401867	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1042242	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1031462	usd
CY2022Q2	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	2343318	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	35540	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	220685	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1200000	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1200000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	198557	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	253636	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7159084	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6450968	usd
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	4651769	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	4577148	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	934861	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	985699	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5586630	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5562847	usd
CY2022Q3	us-gaap	Liabilities Liabilities	12745714	usd
CY2022Q2	us-gaap	Liabilities Liabilities	12013815	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55507082	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55507082	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53007082	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53007082	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	5552	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	5302	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	282402437	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	276989179	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-212044957	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-204345197	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-38190	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-30436	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	70324842	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	72618848	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	83070556	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	84632663	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4556840	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4417505	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2605375	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3055435	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28401	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31733	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	7190616	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	7504673	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7190616	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7504673	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-419182	usd
CY2021Q3	enob	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-2824642	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	95585	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	89739	usd
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	9	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	5623	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	7110	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-509144	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2907262	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7699760	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10411935	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7699760	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-10411969	usd
CY2022Q3	enob	Basic And Diluted Net Loss Per Common Share BasicAndDilutedNetLossPerCommonShare	-0.14
CY2021Q3	enob	Basic And Diluted Net Loss Per Common Share BasicAndDilutedNetLossPerCommonShare	-0.20
CY2022Q3	enob	Weighted Average Number Of Shares Of Common Stock Outstanding Basic And Diluted WeightedAverageNumberOfSharesOfCommonStockOutstandingBasicAndDiluted	55099473	shares
CY2021Q3	enob	Weighted Average Number Of Shares Of Common Stock Outstanding Basic And Diluted WeightedAverageNumberOfSharesOfCommonStockOutstandingBasicAndDiluted	52219661	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7699760	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-10411969	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	7754	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	3993	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7707514	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10415962	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	72618848	usd
CY2022Q3	enob	Stock Issued Pursuant To Warrants Exercised Value StockIssuedPursuantToWarrantsExercisedValue	1625000	usd
CY2022Q3	enob	Shares Issued For Earnout SharesIssuedForEarnout	2762500	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1026008	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7699760	usd
CY2022Q3	enob	Foreign Currency Translation Loss Value ForeignCurrencyTranslationLossValue	-7754	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	70324842	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	174662939	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2727975	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-10411969	usd
CY2021Q3	enob	Foreign Currency Translation Loss Value ForeignCurrencyTranslationLossValue	-3993	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	166974952	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7699760	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-10411969	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	28401	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	31733	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-419182	usd
CY2021Q3	us-gaap	Change In Unrealized Gain Loss On Fair Value Hedging Instruments1 ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1	-2824642	usd
CY2022Q3	enob	Non Cash Compensation NonCashCompensation	1026008	usd
CY2021Q3	enob	Non Cash Compensation NonCashCompensation	2727975	usd
CY2022Q3	enob	Amortization Of Discount On Note Payable AmortizationOfDiscountOnNotePayable	74621	usd
CY2021Q3	enob	Amortization Of Discount On Note Payable AmortizationOfDiscountOnNotePayable	74274	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	3988	usd
CY2021Q3	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1640	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-239703	usd
CY2021Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-157799	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3280877	usd
CY2021Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	227306	usd
CY2022Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	10783	usd
CY2021Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-817554	usd
CY2022Q3	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-185145	usd
CY2021Q3	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-90602	usd
CY2022Q3	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-10981	usd
CY2021Q3	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-1931	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2820299	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5276687	usd
CY2021Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5156	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5156	usd
CY2022Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1625000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1625000	usd
CY2022Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-4925	usd
CY2021Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5517	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1200224	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5287360	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9172142	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20664410	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7971918	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15377050	usd
CY2022Q3	us-gaap	Interest Paid Net InterestPaidNet	30332	usd
CY2021Q3	us-gaap	Interest Paid Net InterestPaidNet	36462	usd
CY2021Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	34	usd
CY2022Q3	enob	Common Shares Issued For Contingent Earn Out Liability CommonSharesIssuedForContingentEarnOutLiability	2762500	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-212044957	usd
CY2022Q3	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zaVTRoSplLT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_86B_zlLA8E7LLkAg">Reclassification</span> – </b>Certain amounts in the prior period financial statements, have been reclassified to conform to the current presentation. For the three months ended September 2021, we reclassified lab expenses of $<span id="xdx_908_eus-gaap--OtherGeneralAndAdministrativeExpense_pp0p0_c20210701__20210930_ze0T2fv15ZA" title="General and administrative expenses">49,192</span>, from general and administrative expenses to research and development expenses<b>. </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> </p>
CY2021Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	49192	usd
CY2022Q3	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zTG1MeWShdK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_864_znKNZmFLaoj5">Accounting Estimates</span> </b>– The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, and fair value of equity instruments issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"/>
CY2022Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	7622223	usd
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	8805495	usd
CY2022Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	93253000	usd
CY2022Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	61571000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	11640000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2605375	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3055435	usd
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4495477	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7116667	shares
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1026008	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2727975	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7699760	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-10411969	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7971918	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-212044957	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	944014	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	944014	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	384393	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	357478	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	559621	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	586536	usd
CY2022Q3	us-gaap	Depreciation Depreciation	26915	usd
CY2021Q3	us-gaap	Depreciation Depreciation	27806	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39953	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	44268	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	260985	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	313836	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1486	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3927	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	44268	usd
CY2022Q3	enob	Period Change PeriodChange	-1486	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-2829	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	39953	usd
CY2022Q2	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	73211000	usd
CY2022Q3	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	73211000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	6752	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	11067	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	11067	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	11067	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	39953	usd
CY2022Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	93253000	usd
CY2017Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On November 13, 2017, Enochian entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”) pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year, and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022,
CY2017Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	70800	usd
CY2019Q2	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On June 19, 2018, Enochian entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Enochian entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050.
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y11M1D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0403	pure
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	180003	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	246004	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	253384	usd
CY2022Q3	enob	Less Imputed Interest LessImputedInterest	120794	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1133418	usd
CY2022Q2	us-gaap	Lessee Finance Sublease Residual Value Guarantee Description LesseeFinanceSubleaseResidualValueGuaranteeDescription	On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent is $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and will increase by 3% each year over the term of the sub-lease. The Company received a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022.
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	43930	usd
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	84083	usd
CY2022Q3	us-gaap	Sublease Income SubleaseIncome	53310	usd
CY2022Q3	enob	Total Net Lease Expense TotalNetLeaseExpense	-9380	usd
CY2021Q3	enob	Total Net Lease Expense TotalNetLeaseExpense	84083	usd
CY2022Q3	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	-9380	usd
CY2021Q3	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	84083	usd
CY2022Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1200000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12030	usd
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6000	usd
CY2022Q3	us-gaap	Interest Expense Other InterestExpenseOther	18182	usd
CY2021Q3	us-gaap	Interest Expense Other InterestExpenseOther	18272	usd
CY2021Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-11-30
CY2021Q1	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.06	pure
CY2022Q3	us-gaap	Shares Issued SharesIssued	74054	shares
CY2022Q3	enob	Market Price MarketPrice	298178	usd
CY2022Q1	us-gaap	Shares Issued SharesIssued	47115	shares
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	299178	usd
CY2021Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	666875	usd
CY2021Q4	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.0399	pure
CY2021Q4	enob	Monthly Installments MonthlyInstallments	56469	usd
CY2022Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	2782	usd
CY2021Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	1267	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	95585	usd
CY2021Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	89739	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55507082	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55507082	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53007082	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53007082	shares
CY2020Q3	us-gaap	Purchase Obligation PurchaseObligation	20000000	usd
CY2021Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-08-01
CY2022Q3	enob	Extinguishment Of Contingent Consideration Liability ExtinguishmentOfContingentConsiderationLiability	419182	usd
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17414	shares
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1026008	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2727975	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5485468	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2019Q4	enob	Upfront Payment UpfrontPayment	10000000	usd
CY2019Q4	enob	Payment For Expenditures PaymentForExpenditures	760000	usd
CY2022Q3	enob	Prevention And Treatment Research PreventionAndTreatmentResearch	0	usd
CY2021Q3	enob	Prevention And Treatment Research PreventionAndTreatmentResearch	75000	usd
CY2021Q3	enob	Initial Payment InitialPayment	600000	usd
CY2021Q4	enob	Paid Initial Payment PaidInitialPayment	600000	usd
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17414	shares
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	0	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	The Company has a consulting agreement for services of a Senior Medical Advisor for up to $210,000 per year on a part-time basis.
CY2022Q3	us-gaap	Related Party Costs RelatedPartyCosts	0	usd
CY2021Q3	us-gaap	Related Party Costs RelatedPartyCosts	2218500	usd

Files In Submission

Name	View Source	Status
0001731122-23-000321-index-headers.html	Edgar Link	pending
0001731122-23-000321-index.html	Edgar Link	pending
0001731122-23-000321.txt	Edgar Link	pending
0001731122-23-000321-xbrl.zip	Edgar Link	pending
e4462_10q.htm	Edgar Link	pending
e4462_ex31-1.htm	Edgar Link	pending
e4462_ex31-2.htm	Edgar Link	pending
e4462_ex32-1.htm	Edgar Link	pending
e4462_ex32-2.htm	Edgar Link	pending
enob-20220930.xsd	Edgar Link	pending
e4462_10q_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
enob-20220930_def.xml	Edgar Link	unprocessable
enob-20220930_lab.xml	Edgar Link	unprocessable
enob-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
enob-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RENB
RENOVARO INC. Stock $renb

2022 Q3 Form 10-Q Financial Statement

#000173112223000321 Filed on March 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RENB RENOVARO INC. Stock $renb

2022 Q3 Form 10-Q Financial Statement

#000173112223000321 Filed on March 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RENB
RENOVARO INC. Stock $renb